Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	International journal of molecular sciences Ročník 18; číslo 2; s. 341
Hlavní autori:	Migliori, Giovanni, Pontali, Emanuele, Sotgiu, Giovanni, Centis, Rosella, D’Ambrosio, Lia, Tiberi, Simon, Tadolini, Marina, Esposito, Susanna
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland MDPI AG 07.02.2017 MDPI
Predmet:	Antitubercular Agents - therapeutic use Diarylquinolines - administration & dosage Diarylquinolines - adverse effects Diarylquinolines - therapeutic use Drug resistance Drug Therapy, Combination Extensively Drug-Resistant Tuberculosis - diagnosis Extensively Drug-Resistant Tuberculosis - drug therapy Extensively Drug-Resistant Tuberculosis - epidemiology Extensively Drug-Resistant Tuberculosis - microbiology Humans Multidrug resistant organisms Mycobacterium Nitroimidazoles - administration & dosage Nitroimidazoles - adverse effects Nitroimidazoles - therapeutic use Oxazoles - administration & dosage Oxazoles - adverse effects Oxazoles - therapeutic use Review Studies Treatment Outcome Tuberculosis Tuberculosis, Multidrug-Resistant - diagnosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - epidemiology Tuberculosis, Multidrug-Resistant - microbiology effectiveness safety tolerability MDR-TB delamanid XDR-TB bedaquiline
ISSN:	1422-0067, 1661-6596, 1422-0067
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!